NewAmsterdam Pharma Company N.V.

NasdaqGM NAMS

NewAmsterdam Pharma Company N.V. Net Cash Used For Investing Activities for the year ending December 31, 2023: USD -24.00 K

NewAmsterdam Pharma Company N.V. Net Cash Used For Investing Activities is USD -24.00 K for the year ending December 31, 2023, a -103.36% change year over year. Net cash used for investing activities is total cash inflows and outflows related to activities intended to generate future income and cash flows from investments.

NewAmsterdam Pharma Company N.V. Net Cash Used For Investing Activities for the year ending December 31, 2022 was USD 715.00 K, a 3,675.00% change year over year.
NewAmsterdam Pharma Company N.V. Net Cash Used For Investing Activities for the year ending December 31, 2021 was USD -20.00 K, a -53.85% change year over year.
NewAmsterdam Pharma Company N.V. Net Cash Used For Investing Activities for the year ending December 31, 2020 was USD -13.00 K.

Key data

Date	Net Cash Used For Investing Activities	Net Cash Used Provided By Financing Activities	Dividends Paid	Capital Expenditure

NasdaqGM: NAMS

NewAmsterdam Pharma Company N.V.

CEO	Dr. Michael Harvey Davidson FACC, Facp., M.D.
IPO Date	Feb. 9, 2021
Location	Netherlands
Headquarters	Gooimeer 2-35
Employees	62
Sector	Health Care
Industries Pharmaceuticals Biotechnology Clinical Trials

Description

NewAmsterdam Pharma Company N.V., a clinical-stage biopharmaceutical company, focuses on improving patient care in populations with metabolic diseases. Its lead investigational candidate, obicetrapib, is a novel, selective inhibitor that targets the Cholesteryl Ester Transfer Protein (CETP), which has been clinically shown to reduce low-density lipoprotein cholesterol (LDL-C) while at the same time substantially increase high-density lipoprotein cholesterol (HDL-C). The company was founded in 2019 and is based in Naarden, the Netherlands.

Key trends

Past 5 years